Cobas ampliprep cobas taqman hcv kit

We analyzed the participants in terms of demographics (i.e., age and gender), anthropometrics (i.e., body weight, height and waist circumference), hemodynamic measurement (i.e., systolic and diastolic blood pressure), and serum biochemical data (i.e., aspartate aminotransfer (AST), asealanine transaminase (ALT), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) triglyceride (TG), and fasting glucose levels). This information was obtained from all patients, and they underwent a detailed examination for serum hepatitis markers, including HBsAg, HBeAg, anti-HCV, HBV DNA, HCV RNA and alpha-fetoprotein (AFP). HBsAg, HBeAg and anti-HCV were detected using commercial assay kits (HBsAg EIA, Abbott, North Chicago, IL; HBeAg EIA, Abbott; anti-HCV, EIA 3.0, Abbott). Levels of HBV DNA were measured by the Cobas Taqman assay (Roche Diagnostics, Branchburg, NJ, USA), with a lower limit of detection of 12 IU/mL. Levels of HCV RNA were detected using a Cobas AmpliPrep/Cobas TaqMan HCV kit (Amplicor, Roche Diagnostics, Branchburg, NJ), with a lower limit of detection of 15 IU/ml.

Serum ALT level was measured by a Hitachi 747 auto-analyzer (Hitachi Ltd.,Tokyo, Japan). In 2004, anti-HCV test was assessed by ELISA utilizing a SP-NANBASE C-96 3.0 plate (General Biological Corp.,Hsinchu, Taiwan). From 2005 to 2011, the anti-HCV test was assessed utilizing Abbott AxSYM HCV 3.0, and the Micro-Enzyme-Immunoassay Analysis (MEIA) was conducted (Abbott, IL, USA). Levels of HCV RNA were detected using a Cobas AmpliPrep/Cobas TaqMan HCV kit (Amplicor, Roche Diagnostics, Branchburg, NJ), with a lower limit of detection of 15 IU/ml.